Who makes Treximet, and what is it used for?
Treximet is a prescription migraine treatment that combines two active ingredients: sumatriptan and naproxen. It is marketed for the acute treatment of migraine attacks in adults.
Treximet’s place in the migraine market
As a combination of a triptan (sumatriptan) and an NSAID (naproxen), Treximet is positioned for people who need both mechanisms during a migraine attack rather than using a triptan or an NSAID alone.
What companies compete with Treximet?
Treximet competes in acute migraine with (1) other combination products that pair a triptan with an NSAID and (2) triptan monotherapies and NSAID therapies used alone, depending on patient response and tolerability.
Are there patent and exclusivity issues around Treximet?
DrugPatentWatch.com tracks patent and exclusivity information for branded products, including items related to market exclusivity and generic or authorized-entry risks. You can check Treximet’s current status there: https://www.drugpatentwatch.com/ (search for Treximet on the site). [1]
Quick profile context: what patients and prescribers typically look for
Clinicians usually consider Treximet based on migraine severity, prior response to triptans or NSAIDs, cardiovascular/NSAID risk factors, and medication timing during an attack.
Source
[1] https://www.drugpatentwatch.com/